Ebola Market Analysis, Size, Share & Growth Forecast 2026–2034

PALM RCT REGEN-EB3 Three-Antibody Cocktail 34 Versus 49 Percent 28-Day Mortality and mab114 35 Versus 49 Percent Versus ZMapp During DRC Outbreak Has Established the Anti-Glycoprotein Neutralising Antibody as Superior Ebola Treatment Over the ZMapp Two-Antibody Standard.The WHO Emergency Use Listing of rapid Ebola antigen tests from Sartorius and OraSure has enabled point-of-care Ebola diagnosis in outbreak settings where laboratory PCR is not quickly deployable, and the sensitivity and specificity validation against rRT-PCR gold standard has supported regulatory approval for outbreak response use. BioFire Defense's FilmArray NGDS panel for Ebola and other haemorrhagic fever viruses, Cepheid's GeneXpert Ebola test, and Roche's LightMix Ebola assay provide the molecular diagnostic options that outbreak response teams deploy at field laboratories to confirm suspected Ebola cases within hours rather than the days that reference laboratory testing requires. The outbreak diagnostic deployment experience from Guinea, Sierra Leone, DRC, and Uganda has refined the sample handling, biosafety level 2 specimen inactivation, and rapid diagnostic protocols that enable Ebola molecular testing in the austere environments that epidemic response operations in resource-limited settings encounter.

Ervebo rVSV-ZEBOV Ring Vaccination 100 Percent Protection in STRIVE Guinea and DRC Kivu Ring Contacts Around Ebola Cases Has Established the Ring Vaccination Strategy as the Outbreak Containment Approach That Pre-Positioned Vaccine Stock and Rapid Response Deployment Enables.The Ervebo vaccine approval by FDA, EMA, and WHO Prequalification for prevention of Ebola virus disease caused by Zaire ebolavirus has provided the first approved Ebola vaccine following the decade of development from the 2014-2016 West Africa epidemic that generated the clinical trial infrastructure and regulatory pathway experience. The ring vaccination strategy deployed in the DRC Kivu outbreak using Ervebo demonstrated real-world vaccine effectiveness of 97.5 percent in contacts and contacts-of-contacts of confirmed cases, validating the ring vaccination approach that limits vaccine supply requirements to the high-risk population directly exposed to confirmed cases. The Janssen Ad26.ZEBOV/MVA-BN-Filo two-dose Ebola vaccine regimen approved by EMA and WHO provides the alternative vaccine option for preventive vaccination of healthcare workers and high-risk populations in endemic regions where ring vaccination response cannot be deployed quickly enough to prevent healthcare worker infections during outbreak response.

REGEN-EB3 Three-Antibody Non-Overlapping GP Epitope Coverage of Fusion Loop, Receptor Binding Domain, and Mucin-Like Domain Providing the Polyclonal Cocktail Approach Has Established the Viral Escape Barrier That Single-Antibody Therapy Cannot Achieve.The PALM trial in the DRC demonstrating 29 percent mortality with REGN-EB3 (Inmazeb from Regeneron) and 35 percent mortality with mAb114 (Ebanga from Ridgeback Biotherapeutics) compared with 74 percent for ZMapp represented the most significant advance in Ebola therapeutics since the identification of the virus. The WHO stockpiling framework for Ebola therapeutics and vaccines and the CEPI funding for Ebola medical countermeasure development provide the preparedness infrastructure that pre-positions treatment supplies across endemic regions to enable rapid deployment at outbreak onset before international supply chains can respond. The Ebola survivor sequelae research investigating the long-term persistence of Ebola virus in immune-privileged sites including the eye, testes, and CNS has led to the monitoring protocols for survivors and has identified the sexual transmission risk in recovered males as the mechanism for the late flare outbreaks that reactivation of persistent infection causes.

For related market intelligence, see the Zika Market.